Sign in
ANTX Stock Price, Chart, Stats & News
AN2 Therapeutics, Inc.
Save
AN2 Therapeutics, Inc. (ANTX) does not currently pay a dividend.
127.97M
Market cap
–
Current P/E
–
Forward P/E
ANTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -56.78% |
ROE | -55.04% |
D/E | – |
Interest coverage ratio | – |
ANTX valuation
P/E | – |
P/S | – |
P/B | 2.08x |
P/CF | -3.71x |
P/FCF | -3.36x |
P/OCF | -3.71x |
PEG | 0.88x |
EV multiple | -3.15x |
About
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Similar securities
Based on sector and market capitalization
Report issue